Trigeminal neuralgia

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
Wednesday, April 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

ZAP Surgical Announces Additional Installation of Its State-of-the-Art ZAP-X Brain Tumor Treatment System in New York State

Retrieved on: 
Tuesday, March 5, 2024
Radiology, Surgery, Oncology, Health, Medical Devices, Robotics, Hospitals, Technology, AVM, TK, Neoplasm, Multimedia, MD, Isotope, NSG, Radiosurgery, Radiation, Spine, Stanford University, Chiari malformation, ZAP, Patient, Brain, Trigeminal neuralgia, SRS, Radiation therapy, Stereotactic surgery, Medical imaging

NSG is a free-standing, privately-owned clinic serving Central New York, the New York Southern Tier, and Northern Pennsylvania.

Key Points: 
  • NSG is a free-standing, privately-owned clinic serving Central New York, the New York Southern Tier, and Northern Pennsylvania.
  • System installation is expected to begin in July, with first patient treatments estimated to commence before the end of the year.
  • “As a procedure with no incisions and no pain, ZAP-X radiosurgery treats patients in what often requires only a single brief outpatient visit.
  • This novel approach aims to maximally safeguard healthy brain tissue and preserve patient cognitive function.

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024
Continuity, Diabetes, Entrepreneurship, Risk, C3, Non-alcoholic fatty liver disease, Epilepsy, FDA, CR2, Anticonvulsant, Inflammation, Neuron, Geographic atrophy, Conference, Paratriathlon, Pain, European, Disease, Cmax, Glycated hemoglobin, Trigeminal neuralgia, FGF21, Steatosis, Therapy, Computational biology, Exophthalmos, TED, Diplopia, Varenicline, Smoking, Injection, AAV, CNS, DSM-IV codes, Patient, Graves' ophthalmopathy, Medicine, Seizure, Glucokinase, Neurology, CR1, NASH, Insulin, Brain, GMP, Trigeminal nerve, Ophthalmology, Pathology, Fibrosis, Pharmaceutical industry

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for common diseases affecting millions of people around the world, today provided an update on its pipeline of gene therapies for prevalent conditions including geographic atrophy, thyroid eye disease, diabetes, NASH, trigeminal neuralgia and epilepsy. Kriya is advancing the first of its gene therapy product candidates into the clinic in 2024 and expects up to five programs in the clinic by the end of 2025.

Key Points: 
  • Kriya’s pipeline includes gene therapies across three major therapeutic areas: ophthalmology, metabolic disease and neurology.
  • Its programs share the following features: direct-to-tissue delivery, validated biology, de-risked clinical and regulatory paths and large commercial markets.
  • Dr. Ramaswamy will share further information on Kriya’s portfolio during his presentation at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th at 9:00 AM PT in San Francisco, California.
  • A significant proportion of patients suffer from refractory epilepsy, many of whom are candidates for invasive neurosurgery.

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Capsaicin, Marketing, European Commission, INN, HIV/AIDS, Infection, Diabetic neuropathy, ATC, Pain, Varicella zoster virus, International, European, Diabetes, Language, Shingles, Red, TRPV1, Trigeminal neuralgia, Neuropathic pain, HIV, Select, Committee, Patient, Risk management, Anatomy, Medicine, IIA, CHMP, Skin, Medical device

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Chills, Patient, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Fever, Fatigue, Shingles, Human, ATC, Antibody, Bone marrow, Pain, Chronic pain, International, Injection, Headache, Disease, Ageing, Nausea, Language, HZ, Vaccination, Swelling, Red, PHN, Trigeminal neuralgia, European Medicines Agency, Chickenpox, Myalgia, Select, Anatomy, Vomiting, IIA, Vaccine

Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Shingrix, herpes zoster vaccine (recombinant, adjuvanted), Date of authorisation: 21/03/2018, Revision: 10, Status: Authorised

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

Retrieved on: 
Thursday, November 2, 2023
Chronic pain, MDPI, Low back pain, MD, Diclofenac, Trigeminal neuralgia, Lidocaine, Skin, PALO, Biomedical Research, Clinical pharmaceutical scientist, Pain, Dermis, AAPS, Medical imaging

A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion.

Key Points: 
  • A set of studies assessed drug delivery from SP-103, ZTlido and control (Pennsaid®, 2% diclofenac) using open flow microperfusion.
  • Interstitial fluid from the dermis, subcutaneous adipose tissue, and muscle was continuously sampled to assess drug penetration in all tissue layers.
  • Current results of skin penetration studies for the first time had demonstrated uptake of lidocaine by muscle tissue via a passive diffusion through the skin.
  • We are very excited about these results supporting our clinical development plans,” said Dmitri Lissin, MD, Chief Medical Officer at Scilex.

ZAP Surgical Announces Upcoming Installation of Next-Generation ZAP-X Gyroscopic Radiosurgery in Ankara, Turkey

Retrieved on: 
Tuesday, September 26, 2023
Radiology, Biotechnology, Surgery, Oncology, Health, Medical Devices, Hospitals, Other Health, SRS, Hacettepe University, Trigeminal neuralgia, Breast, Uveal melanoma, Multimedia, Brain, Radiation therapy, Radiosurgery, Teaching hospital, Lung, Chiari malformation, Stereotactic surgery, Management of prostate cancer, AVM, Patient, ZAP, Isotope, Medical imaging

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that Hacettepe University Hospital in Ankara, Turkey is slated to install the novel ZAP-X® Gyroscopic Radiosurgery® platform before the end of the year.
  • View the full release here: https://www.businesswire.com/news/home/20230926608561/en/
    ZAP-X Gyroscopic Radiosurgery platform.
  • For select indications, radiosurgery has proven to provide equivalent to superior outcomes compared to costly and potentially debilitating surgeries.
  • “With the addition of ZAP-X, they will further reinforce their reputation as global center of medical excellence.”

Trigeminal Neuralgia Drug Pipeline Research Report 2023: Comprehensive Insights on 10 Companies and 10 Pipeline Drugs Featuring Biogen, Biohaven Pharmaceuticals, Noema Pharma, & Pfizer - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 12, 2023
Health, Pharmaceutical, Biogen, II, Mergers and acquisitions, Trigeminal neuralgia, Discovery, Therapy, III, News, Rimegepant, Nursing, Pharmaceutical industry

The "Trigeminal Neuralgia- Pipeline Insight, 2023" report offers comprehensive insights into the Trigeminal Neuralgia pipeline landscape, featuring information on more than 10 companies and over 10 pipeline drugs.

Key Points: 
  • The "Trigeminal Neuralgia- Pipeline Insight, 2023" report offers comprehensive insights into the Trigeminal Neuralgia pipeline landscape, featuring information on more than 10 companies and over 10 pipeline drugs.
  • Leading companies and academic institutions are dedicated to addressing challenges and exploring opportunities that can shape the future of Trigeminal Neuralgia research and development.
  • The therapies currently in development focus on innovative approaches to enhance the treatment and management of Trigeminal Neuralgia.
  • This segment of the report provides insights about the different Trigeminal Neuralgia drugs segregated based on following parameters that define the scope of the report, such as:
    There are approx.

EQS-News: Biotest AG: Biotest treats first shingles patient with Varitect® CP in VARIZOSTA study

Retrieved on: 
Tuesday, September 5, 2023
Shingles, Viral disease, VZV, CP, AG, Trigeminal neuralgia, HIV disease progression rates, Patient, Risk, Chronic pain, Immunodeficiency, Skin, Safety, Disease, Vaccine

High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain.

Key Points: 
  • High medical need in severe cases of herpes zoster (shingles) and resulting severe chronic nerve pain.
  • Biotest AG today announces that the first patient has been documented in the prospective, multicentre observational study VARIZOSTA conducted by Biotest.
  • The study will evaluate the use of the herpes zoster virus-specific hyperimmunoglobulin Varitect® CP (VZV-IgG) in complex herpes zoster, particularly in patients with a high risk constellation for severe disease progression.
  • The non-interventional study, in which 120 patients treated with VZV-IgG and 40 control patients are included, is being conducted at about 15 centres in Germany.

American Shared Hospital Services Subsidiary, GK Financing LLC, Introduces a New Dedicated Online Platform Redefining Access to Gamma Knife Radiosurgery Treatment Financing

Retrieved on: 
Wednesday, August 16, 2023
Esprit, Neoplasm, Health care, AMS, Trigeminal neuralgia, GK, DSM-IV codes, Brain, NYSE, Patient, SAN, Chiari malformation, Emergency Hospital Service, Leeds Gamma Knife Centre, Social media, Medical imaging, Radiosurgery, Neuroscience

The Cost of Medical Radiosurgery Treatment: A Challenge for Many

Key Points: 
  • The Cost of Medical Radiosurgery Treatment: A Challenge for Many
    For countless patients facing brain cancer and functional disorders, or seeking life-changing non-invasive radiosurgery treatments, the cost of care can be overwhelming.
  • Gamma Knife radiosurgery is an innovative and non-invasive medical technique that uses precisely targeted radiation beams to treat brain disorders such as tumors, vascular malformations, and trigeminal neuralgia.
  • Remote treatment planning capabilities increases and improves workflow efficiency, as well as providing remote accessibility and collaboration tools designed to meet the needs of changing environments.
  • Peter Gaccione, CEO of American Shared Hospital Services and President, GK Financing, stated, “GKF has had long established partnerships with leading healthcare providers specializing in Gamma Knife radiosurgery and other critical medical procedures.